{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:39:48Z","timestamp":1780468788747,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00262-022-03154-z","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T16:02:35Z","timestamp":1643558555000},"page":"2293-2300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immune escape mechanism behind resistance to anti-PD-1 therapy in gastrointestinal tract metastasis in malignant melanoma patients with multiple metastases"],"prefix":"10.1007","volume":"71","author":[{"given":"Misato","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2565-154X","authenticated-orcid":false,"given":"Kosaku","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuharu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung Kyi Thar","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonobu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Momma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenichiro","family":"Saze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"key":"3154_CR1","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"3154_CR2","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A et al (2016) Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600\u20131609. https:\/\/doi.org\/10.1001\/jama.2016.4059","journal-title":"JAMA"},{"key":"3154_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","volume":"11","author":"JH Lee","year":"2020","unstructured":"Lee JH, Shklovskaya E, Lim SY et al (2020) Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nat Commun 11:1897. https:\/\/doi.org\/10.1038\/s41467-020-15726-7","journal-title":"Nat Commun"},{"key":"3154_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA et al (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707\u2013723. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017","journal-title":"Cell"},{"key":"3154_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin MM, Zhang X, Schuster H et al (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577\u2013581. https:\/\/doi.org\/10.1038\/nature13988","journal-title":"Nature"},{"key":"3154_CR6","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/s1470-2045(20)30234-5","volume":"21","author":"M Ochoa De Olza","year":"2020","unstructured":"Ochoa De Olza M, Navarro Rodrigo B, Zimmermann S et al (2020) Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncol 21:e419\u2013e430. https:\/\/doi.org\/10.1016\/s1470-2045(20)30234-5","journal-title":"Lancet Oncol"},{"key":"3154_CR7","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY et al (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:10501. https:\/\/doi.org\/10.1038\/ncomms10501","journal-title":"Nat Commun"},{"key":"3154_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10120-020-01151-8","volume":"24","author":"K Mimura","year":"2021","unstructured":"Mimura K, Kua LF, Xiao JF et al (2021) Combined inhibition of PD-1\/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models. Gastric Cancer 24:611\u2013623. https:\/\/doi.org\/10.1007\/s10120-020-01151-8","journal-title":"Gastric Cancer"},{"key":"3154_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.Cd-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H et al (2017) Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov 7:188\u2013201. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-1223","journal-title":"Cancer Discov"},{"key":"3154_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A et al (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14:399\u2013416. https:\/\/doi.org\/10.1038\/nrclinonc.2016.217","journal-title":"Nat Rev Clin Oncol"},{"key":"3154_CR11","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1158\/1541-7786.Mcr-20-0308","volume":"18","author":"E Endo","year":"2020","unstructured":"Endo E, Okayama H, Saito K et al (2020) A TGF\u03b2-dependent stromal subset underlies immune checkpoint inhibitor efficacy in dna mismatch repair-deficient\/microsatellite instability-high colorectal cancer. Mol Cancer Res 18:1402\u20131413. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-20-0308","journal-title":"Mol Cancer Res"},{"key":"3154_CR12","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.21873\/anticanres.15303","volume":"41","author":"P Neupane","year":"2021","unstructured":"Neupane P, Mimura K, Nakajima S et al (2021) The expression of immune checkpoint receptors and ligands in the colorectal cancer tumor microenvironment. Anticancer Res 41:4895\u20134905. https:\/\/doi.org\/10.21873\/anticanres.15303","journal-title":"Anticancer Res"},{"key":"3154_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113023","volume":"9","author":"F Gebauer","year":"2014","unstructured":"Gebauer F, Wicklein D, Horst J et al (2014) Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. PLoS ONE 9:e113023. https:\/\/doi.org\/10.1371\/journal.pone.0113023","journal-title":"PLoS ONE"},{"key":"3154_CR14","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.3892\/ijo.2019.4779","volume":"54","author":"Y Nakayama","year":"2019","unstructured":"Nakayama Y, Mimura K, Tamaki T et al (2019) PhosphoSTAT1 expression as a potential biomarker for antiPD1\/antiPDL1 immunotherapy for breast cancer. Int J Oncol 54:2030\u20132038. https:\/\/doi.org\/10.3892\/ijo.2019.4779","journal-title":"Int J Oncol"},{"key":"3154_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdx686","volume":"29","author":"A Rotte","year":"2018","unstructured":"Rotte A, Jin JY, Lemaire V (2018) Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 29:71\u201383. https:\/\/doi.org\/10.1093\/annonc\/mdx686","journal-title":"Ann Oncol"},{"key":"3154_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J et al (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26:923\u2013937. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.018","journal-title":"Cancer Cell"},{"key":"3154_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura K, Teh JL, Okayama H et al (2018) PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Sci 109:43\u201353. https:\/\/doi.org\/10.1111\/cas.13424","journal-title":"Sci"},{"key":"3154_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571. https:\/\/doi.org\/10.1038\/nature13954","journal-title":"Nature"},{"key":"3154_CR19","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1158\/0008-5472.Can-13-0023","volume":"73","author":"TL Yeung","year":"2013","unstructured":"Yeung TL, Leung CS, Wong KK et al (2013) TGF-\u03b2 modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res 73:5016\u20135028. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-0023","journal-title":"Cancer Res"},{"key":"3154_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD (2020) Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37:443\u2013455. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.017","journal-title":"Cancer Cell"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03154-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03154-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03154-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T11:04:56Z","timestamp":1660302296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03154-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3154"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03154-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,30]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the ethical principles of the 1964 Declaration of Helsinki and its later amendments, and was approved by the Fukushima Medical University Research Ethics Committee (Reference No. 2020\u2013257).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None of the patients included in this study have declared objection against the use of their specimens and clinical data for research and publication, as stated in the consent approved by the Fukushima Medical University Research Ethics Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}